RXD:NYE-ProShares UltraShort Health Care (USD)

ETF | Trading--Inverse Equity |

Last Closing

USD 12.5

Change

-0.54 (-4.14)%

Market Cap

N/A

Volume

0.02M

Analyst Target

N/A
Analyst Rating

N/A

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2025-05-16 )

Largest Industry Peers for Trading--Inverse Equity

Symbol Name Price(Change) Market Cap
SH ProShares Short S&P500

-0.25 (-0.60%)

USD 1.42B
PSQ ProShares Short QQQ

-0.14 (-0.39%)

USD 0.67B
SPXU ProShares UltraPro Short S&P50..

-0.36 (-1.85%)

USD 0.52B
SOXS Direxion Daily Semiconductor B..

+0.05 (+0.43%)

USD 0.46B
YANG Direxion Daily FTSE China Bear..

+0.38 (+1.08%)

USD 0.27B
SDOW ProShares UltraPro Short Dow30

-1.09 (-2.31%)

USD 0.23B
RWM ProShares Short Russell2000

-0.15 (-0.76%)

USD 0.21B
FNGD MicroSectors FANG+ Index -3X I..

-0.10 (-1.15%)

USD 0.18B
SPDN Direxion Daily S&P 500® Bear ..

-0.06 (-0.55%)

USD 0.18B
DOG ProShares Short Dow30

-0.20 (-0.75%)

USD 0.14B

ETFs Containing RXD

RLD:CA 0.00 % 0.61 %

N/A

N/A

Market Performance

  Market Performance vs. Industry/Classification (Trading--Inverse Equity) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 5.04% 96% N/A 74% C
Dividend Return N/A N/A N/A N/A N/A
Total Return 5.04% 96% N/A 73% C
Trailing 12 Months  
Capital Gain 18.34% 98% N/A 85% B
Dividend Return 2.76% 60% D- 51% F
Total Return 21.11% 98% N/A 85% B
Trailing 5 Years  
Capital Gain -54.29% 87% B+ 7% C-
Dividend Return 3.20% 77% C+ 6% D-
Total Return -51.09% 87% B+ 6% D-
Average Annual (5 Year Horizon)  
Capital Gain 67.10% 39% F 96% N/A
Dividend Return 68.58% 39% F 96% N/A
Total Return 1.48% 58% F 35% F
Risk Return Profile  
Volatility (Standard Deviation) 432.91% 63% D 3% F
Risk Adjusted Return 15.84% 52% F 34% F
Market Capitalization N/A N/A N/A N/A N/A

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:

There is nothing we particularly like

What to not like:
Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.